Peptide T

Literature References: Octapeptide segment of the human immunodeficiency virus (HIV) envelope glycoprotein (gp 120); named peptide T because of its high threonine content. Has been reported to block the in vitro binding of HIV envelope to human leukocyte receptor CD4. Isolation, neuropharmacology and anti-HIV activity of peptide and analogs: C. B. Pert et al., Proc. Natl. Acad. Sci. USA 83, 9254 (1986). Characterization of active core structure, T[4-8], and chemotactic effects: C. B. Pert, M. R. Ruff, Clin. Neuropharmacol. 9, Suppl. 4, 482 (1986). Chemotactic effects and structural homology with vasoactive intestinal peptide (VIP), q.v.: M. R. Ruff et al., FEBS Lett. 211, 17 (1987). Competitive binding studies at VIP receptor: T. D. Nguyen, Peptides 9, 425 (1988). Structural homology with thymosin a1, q.v.: T. D. Nguyen, L. A. Scheving, Biochem. Biophys. Res. Commun. 145, 884 (1987). Evaluation of anti-HIV activity: J. Sodroski et al., Lancet 1, 1428 (1987). Clinical evaluation in treatment of AIDS: L. Wetterberg et al., ibid. 159. Chromatographic purification of [D-ala1] peptide T amide, a metabolically stable and more potent analog of peptide T: T. R. Burke, M. Knight, J. Chromatogr. 411, 431 (1987). Blood to brain transport of the amide in mice: C. M. Barrera et al., Brain Res. Bull. 19, 629 (1987). Brief review of debate over effectiveness of peptide T: D. M. Barnes, Science 237, 128 (1987).